Tesamorelin (10mg)

Recent research & studies

• The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment. — PubMed • Stewart CE et al. • eNeurologicalSci • 2026 Sep

  Cognitive decline with age and other clinical conditions are linked with reduced hypothalamic-pituitary-adrenal (HPA) axis function. Stimulating the HPA axis with supplemental growth hormone (GH) treatment can improve cognition, however, potential direct effects of stimulation with growth hormone releasing hormone…

• Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol. — PubMed • Erlandson KM et al. • BMJ Open • 2026 Jul 8

  Background: The Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH) study is a randomised controlled trial with the overall goal of examining the combined effect of exercise and the growth hormone-releasing hormone analogue tesamorelin on…

• Body Composition and Adipose Tissue in HIV — ClinicalTrials.gov • Terminated • Phase4 • May 19, 2026

  In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity. This study is a single arm prospective study of…

• Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV — ClinicalTrials.gov • Recruiting • Phase2 • May 19, 2026

  People with HIV experience earlier impairments in physical function compared to people in the general population. They also exhibit an earlier presentation and more rapid development of frailty, a multisystemic syndrome of aging characterized by reduced activity, fatigue, slowness, weakness,…

• Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. — PubMed • Villegas Meza AD et al. • JBJS Rev • 2026 May 1

  Background: Injectable peptides are increasingly promoted for musculoskeletal recovery, tissue repair, and performance enhancements; however, clinical adoption has outpaced high-quality evidence and regulatory consensus. Purpose: To summarize contemporary human and translational evidence (January 1, 2020-August 31, 2025) for injectable peptides…

• Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) — ClinicalTrials.gov • Recruiting • Phase2 • March 19, 2026

  This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease. Participants receive tesamorelin or matching placebo for 52 weeks, with standardized lifestyle counseling in…

These are third-party research studies presented for informational purposes. They are not endorsements and do not constitute medical advice or claims about any product.